NASH CLINICAL
NASH Clinical comprises a global network of clinicians, investigators and experts in the NASH field. Emphasizing the importance of the Patients Care Path, a firm collaboration is set up with the participating clinicians, involving Primary Care Physicians, Endocrinologists, Diabetologists, Hepatologists and Gastroenterologists. NASH Clinical aims to share insights about this endemic disease, to collaboratively create easy-and-accurate diagnostic tools to identify these patients, and to conduct clinical trials to mitigate the potentially deleterious outcome of this disease.
DAshboard | interactive map of oUR GLOBAL REACH and experience
NASH WEBINAR Series: WEbinar 2
PRomising Phase 2B trial results of Lanifibranor in NASH
February 1st 2022 | 17.00 - 18.00 CET
Topic:
In this webinar Prof. Sven Francque will be discussing the phase 2 trial results of the Pan-PPAR Agonist Lanifibranor in nonalcoholic steatohepatitis (NASH) patients. Currently there is an unmet need of management of NASH. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH and shows promising results as treatment.
Speaker: Prof. Sven Francque
Host: Dr. Manuel Castro Cabezas
Co-host: Prof. Christophe Moreno
In this webinar Prof. Sven Francque will be discussing the phase 2 trial results of the Pan-PPAR Agonist Lanifibranor in nonalcoholic steatohepatitis (NASH) patients. Currently there is an unmet need of management of NASH. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH and shows promising results as treatment.
Speaker: Prof. Sven Francque
Host: Dr. Manuel Castro Cabezas
Co-host: Prof. Christophe Moreno
NASH CLinical webinar series
This webinar is the second of the NASH webinar series, each focusing on recent developments or publications on nonalcoholic steatohepatitis (NASH). The topics and publications are selected by KOLs of NASH Clinical based on relevant ground-breaking NASH research in a high-impact journal. During these webinars we offer you the opportunity to interact with original authors and experts in the NASH field.
NASH CLinical video
Every now and then an article on NASH is published which is relevant for both clinicians and scientists. "Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations from the Liver Forum", by Cheung et al* is such an article. When can we speak of a real improvement due to treatment in NASH patients? If you happen to have 5 minutes left, have a look at this NASH Clinical video! We think it is worthwhile.
* Journal of the American College of Cardiology.
2019 By the American College of Cardiolofy Foundation - Published by Elsavier.
* Journal of the American College of Cardiology.
2019 By the American College of Cardiolofy Foundation - Published by Elsavier.
| defining_improvement_in_nonalcoholic_steatohepatitis |
WHAT IS NASH?
|
NASH is an acronym that stands for Non-Alcoholic SteatoHepatitis. It is the most severe form of non-alcoholic fatty liver disease (NAFLD), and is characterized by the presence of an abnormal accumulation of fat in the liver which in some individuals can progress to liver cell injury (hepatocellular ballooning) and inflammation. As NASH evolves, over time it can result in excessive scarring in the liver (fibrosis), a natural response to injury which can lead to liver cirrhosis or liver cancer.
NAFLD is often associated with insulin resistance and is strongly associated with type 2 diabetes mellitus and obesity. In addition to being at risk for NASH, cirrhosis and its complications, NAFLD patients are also at higher risk of cardiovascular diseases (CVD), including coronary heart disease and stroke. NAFLD confers increased cardiovascular disease risk independent of traditional cardiovascular risk factors and metabolic syndrome. Individuals with NASH, have a high frequency of metabolic co-morbidities and could place a growing strain on health-care systems from their need for management. While awaiting the development effective therapies, this disease warrants the attention of primary care physicians, specialists and health policy makers. |
Bron: The NASH education program
|
lifestyle disease
NASH is closely related to the epidemic of obesity, pre-diabetes, and diabetes, and can be defined as the liver manifestation of the metabolic syndrome. It is heavily influenced by lifestyle (e.g. chronic excessive calorie intake, sedentary activity) and is distinct from other fatty liver diseases caused by alcohol abuse or medication side effects
Nowadays NASH is the 2nd most common indication for liver transplantation in the USA. The ongoing obesity epidemic makes NASH a serious burden of disease. So, there is an urgent need for effective drugs.
Nowadays NASH is the 2nd most common indication for liver transplantation in the USA. The ongoing obesity epidemic makes NASH a serious burden of disease. So, there is an urgent need for effective drugs.
WHY NASH CLINICAL?
Interdisciplinary collaboration is needed to combat NASH and consequently we have created NASH clinical network. The aim of this network is to share insights about this endemic disease, to collaboratively create easy-and-accurate diagnostic tools to identify these patients, and to conduct clinical trials to mitigate the potentially deleterious outcome of this disease.
THE nASH CLINICAL TEAM
Dr. Manuel Castro Cabezas, MD. Associate Professor of Medicine at Erasmus Medical Center, Rotterdam, the Netherlands Internist-endocrinologist/vascular specialist at Franciscus Gasthuis Ziekenhuis, Rotterdam Scientific Officer, Julius Clinical Academic Research Organization |
Prof. Dr. Christophe Moreno, MD. Professor in Gastroenterology and Hepatology Clinical Director of the Liver Unit at CUB Hôpital Erasme, Brussels, Belgium Consultant to the NASH Clinical team |
Prof. Dr. Diederick E. Grobbee, MD. Professor of Clinical Epidemiology, UMC Utrecht Past president European Association for Preventive Cardiology, ESC. Chief Scientific Officer, Julius Clinical Academic Research Organization |
Dr. Leyla Kragten-Tabatabaie Director Scientific Networks, Julius Clinical Academic Research Organization Board of Directors, ReSViNET foundation |
Prof. Dr. Joost Hoekstra Professor of Medicine, University of Amsterdam’s Faculty of Medicine (AMC-UvA) Scientific Officer, Julius Clinical Academic Research Organization |
|
| ||
